Samsung Biologics (KRX:207940) posted a 29.1% year-over-year rise in second-quarter net income attributable to shareholders of the parent to 430.7 billion won from 333.6 billion won.
Revenue increased 30.2% to 1.321 trillion won from 1.014 trillion won a year earlier, according to a Thursday filing with the Korea Exchange.